STK-001 Gains FDA Breakthrough Designation as Potential Disease-Modifying Treatment for Dravet Syndrome

Stoke Therapeutics is preparing for a phase 3 registrational study to further assess STK-001, with results from open-label extensions showing sustained seizure reductions and a well-tolerated safety profile.:

Source: Neurology Read More

Previous PostREGENXBIO Advances AFFINITY DUCENNE Gene Therapy Trial to Pivotal Stage with Positive Phase 1/2 Results
Next PostSystem Integration: How AI Is Weaving Itself into Neurology

STK-001 Gains FDA Breakthrough Designation as Potential Disease-Modifying Treatment for Dravet Syndrome

Previous PostREGENXBIO Advances AFFINITY DUCENNE Gene Therapy Trial to Pivotal Stage with Positive Phase 1/2 Results

Next PostSystem Integration: How AI Is Weaving Itself into Neurology

Related Posts

<![CDATA[FDA Requests HOPE-3 Clinical Study Report for Deramiocel BLA in DMD Cardiomyopathy]]>

<![CDATA[Shifting Alzheimer Detection Upstream Using Digital Cognitive Assessments: John Showalter, MD, MSIS]]>

<![CDATA[LIONHEART, VISION-DMD and the Integration of Cardiac Outcomes in DMD Trials]]>

Categories